109451
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
围手术期持续输注艾司氯胺酮对乳腺癌患者术后抑郁的影响：一项随机对照双盲试验
Authors Shen M , Xuan Y, Chen K , Lei W, Huang Y, Wang J, Sun J, Lu X
Received 16 May 2025
Accepted for publication 23 October 2025
Published 29 October 2025 Volume 2025:19 Pages 9685—9695
DOI https://doi.org/10.2147/DDDT.S540781
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Anastasios Lymperopoulos
Mengting Shen,1,2 Ye Xuan,1,2 Kaiyu Chen,1,2 Weiping Lei,2 Yaqin Huang,2 Junhui Wang,3 Jianliang Sun,1,2,* Xinlei Lu2,*
1The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou First People’s Hospital, Hangzhou, Zhejiang, People’s Republic of China; 2Department of Anesthesiology, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, People’s Republic of China; 3Affiliated Luqiao Hospital, HangZhou City University School of Medicine, Taizhou, Zhejiang, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Jianliang Sun, Email jxmzsjl@163.com Xinlei Lu, Email mazuiluxinlei@163.com
Background: Comorbid depressive symptoms are prevalent in patients with breast cancer, which adversely impacts postoperative recovery outcomes. Esketamine has emerged as a promising intervention for perioperative depression due to its rapid and sustained effects. This study aims to investigate the impact of the continuous intravenous infusion of esketamine during the perioperative period on postoperative depressive symptoms in breast cancer patients.
Methods: In this randomized, double-blind, controlled trial, 96 female patients aged 18– 65 years undergoing unilateral modified radical mastectomy were enrolled. Participants were randomly assigned to one of two groups. The esketamine group received 0.5 mg/kg and 0.25 mg/kg/h esketamine and the normal saline group received 5 mL and 0.25 mL/kg/h normal saline during anesthesia induction and maintenance, respectively. The primary outcome was the Hamilton Depression Rating Scale (HAMD-17) score on postoperative day 30 (POD-30). Secondary outcomes included HAMD-17 scores on POD 1 and 3; self-Rating Depression Scale (SDS) scores on POD 1, 3, and 30; serum levels of brain-derived neurotrophic factor (BDNF) and serotonin (5-hydroxytryptamine, 5-HT) after surgery; relative changes in heart rate (HR) and mean arterial pressure (MAP) before and after intubation; time to awakening; Visual Analog Scale (VAS) pain scores; and adverse events related to esketamine.
Results: The HAMD-17 score on POD-30 was significantly lower in the esketamine group [3.00 (2.08– 4.10)] than in the normal saline group [5.00 (4.00– 6.20)]. Regarding secondary outcomes, HAMD-17 scores on POD 1 and 3 were significantly lower in the esketamine group. SDS scores on POD 1, 3, and 30 were also significantly lower in the esketamine group. Compared with the saline group, the esketamine group exhibited significantly higher postoperative levels of BDNF and serotonin. Additionally, VAS scores at 30 minutes after extubation were significantly lower in the esketamine group. There was no significant difference in the incidence of adverse reactions between the two groups.
Conclusion: Perioperative continuous administration of esketamine reduces postoperative depression scores in patients undergoing breast cancer surgery.
Trial Registration: Chinese Clinical Trial Registry. Identifier: ChiCTR2200061575.
Keywords: esketamine, perioperative period, breast cancer, postoperative depression, brain-derived neurotrophic factor, 5-hydroxytryptamine, pain
1The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou First People’s Hospital, Hangzhou, Zhejiang, People’s Republic of China; 2Department of Anesthesiology, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, People’s Republic of China; 3Affiliated Luqiao Hospital, HangZhou City University School of Medicine, Taizhou, Zhejiang, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Jianliang Sun, Email jxmzsjl@163.com Xinlei Lu, Email mazuiluxinlei@163.com
Background: Comorbid depressive symptoms are prevalent in patients with breast cancer, which adversely impacts postoperative recovery outcomes. Esketamine has emerged as a promising intervention for perioperative depression due to its rapid and sustained effects. This study aims to investigate the impact of the continuous intravenous infusion of esketamine during the perioperative period on postoperative depressive symptoms in breast cancer patients.
Methods: In this randomized, double-blind, controlled trial, 96 female patients aged 18– 65 years undergoing unilateral modified radical mastectomy were enrolled. Participants were randomly assigned to one of two groups. The esketamine group received 0.5 mg/kg and 0.25 mg/kg/h esketamine and the normal saline group received 5 mL and 0.25 mL/kg/h normal saline during anesthesia induction and maintenance, respectively. The primary outcome was the Hamilton Depression Rating Scale (HAMD-17) score on postoperative day 30 (POD-30). Secondary outcomes included HAMD-17 scores on POD 1 and 3; self-Rating Depression Scale (SDS) scores on POD 1, 3, and 30; serum levels of brain-derived neurotrophic factor (BDNF) and serotonin (5-hydroxytryptamine, 5-HT) after surgery; relative changes in heart rate (HR) and mean arterial pressure (MAP) before and after intubation; time to awakening; Visual Analog Scale (VAS) pain scores; and adverse events related to esketamine.
Results: The HAMD-17 score on POD-30 was significantly lower in the esketamine group [3.00 (2.08– 4.10)] than in the normal saline group [5.00 (4.00– 6.20)]. Regarding secondary outcomes, HAMD-17 scores on POD 1 and 3 were significantly lower in the esketamine group. SDS scores on POD 1, 3, and 30 were also significantly lower in the esketamine group. Compared with the saline group, the esketamine group exhibited significantly higher postoperative levels of BDNF and serotonin. Additionally, VAS scores at 30 minutes after extubation were significantly lower in the esketamine group. There was no significant difference in the incidence of adverse reactions between the two groups.
Conclusion: Perioperative continuous administration of esketamine reduces postoperative depression scores in patients undergoing breast cancer surgery.
Trial Registration: Chinese Clinical Trial Registry. Identifier: ChiCTR2200061575.
Keywords: esketamine, perioperative period, breast cancer, postoperative depression, brain-derived neurotrophic factor, 5-hydroxytryptamine, pain